In this cohort of 18 patients, prior to treatment initiation, HER2 amplification was detectable in cfDNA in only 50% of patients (9/18) (despite HER2 amplification detection in tumour tissue in all cases (18/18)). This evidence concerns the gene ERBB2 and neoplasm.